Amneal Pharmaceuticals Inc (AMRX)
Amneal Pharmaceuticals, Inc. is a healthcare company focused on the development, manufacture, marketing, and distribution of pharmaceutical products. Its portfolio includes generics, injectables, biosimilars, and specialty branded medicines sold in the United States, India, Ireland, and other international markets. The company operates through three business segments: Affordable Medicines, Specialty, and AvKARE. Affordable Medicines covers a broad range of dosage forms and delivery systems, including oral solids, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment centers on therapies for central nervous system and endocrine disorders, including products used in Parkinson’s disease and hypothyroidism. AvKARE serves government and institutional customers with pharmaceuticals, medical and surgical products, and related packaging and distribution services. Amneal was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMRX
|
$17.15
|
-19.8% Downside
|
Overvalued
|
$24.29
|
13.6% Upside
|
Fair
|
Great
|
0.0%
|
February 26, 2027
|
56.7x
|
14.2x
|
2.4x
|
7.561 B
|
10.791 B
|
30.0%
|
61.8%
|
2.9
|
28.8%
|